Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Normal human melanocytes can avoid cell death through multiple pathways.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

WYE-130600 may cause skin thickening and irritation.

Topoisomerase inhibitors can cause hair loss, skin rash, hand-foot syndrome, and nail changes.

High DKK1 levels predict worse survival in head and neck cancer.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

ODC overexpression in hair cells increases tumor growth by reducing Notch signaling.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

ICP5249 helps hair grow by activating a specific cell pathway.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.

Protein Kinase Cε increases skin sensitivity to UV damage and skin cancer risk.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

Keratinocyte Growth Factor-Hair Serum may help prevent hair loss during chemotherapy, but more research is needed.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Upadacitinib improved multiple immune-related conditions in one patient.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Targeted therapy for skin cancer is complex due to the role of the hedgehog pathway in both cancer and hair growth.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

HDAC1 is crucial for skin development and preventing tumors.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

KY19382 speeds up wound healing by activating a specific cell signaling pathway.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.